DENDRITIC CELLS VERSUS MONTANIDE TO STIMULATE ANTI-TUMOR IMMUNITY IN MELANOMA

树突状细胞与 Montanide 刺激黑色素瘤的抗肿瘤免疫力

• 批准号: 7718398
• 负责人: Nina Bhardwaj
• 金额: $ 0.04万
• 依托单位: NEW YORK UNIVERSITY SCHOOL OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-04-01 至 2009-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7718398
• 关键词: Address; Adjuvant; Biological Assay; CD8B1 gene; Cells; Computer Retrieval of Information on Scientific Projects Database; Cytolysis; Cytotoxic T-Lymphocytes; Dendritic Cells; End Point; Funding; Grant; HLA A*0201 antigen; Immunotherapy; Institution; Interferon Type II; Keyhole Limpet Hemocyanin; Measures; Patients; Peptides; Peripheral Blood Lymphocyte; Physiologic pulse; Pulse taking; Randomized; Research; Research Personnel; Resources; Source; Staging; T-Lymphocyte; Toxic effect; Tumor Immunity; United States National Institutes of Health; Upper arm; Vaccines; base; immunogenicity; melanoma; response; tumor

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This study hypothesizes that vaccines prepared with dendritic Ag-presenting cells pulsed with candidate melanoma-specific peptides' keyhole limpet hemocyanin (KLH) are superior "boosters" of the cytotoxic T-lymphocyte response as compared to vaccines prepared with the same peptides with KLH and QS-21 as adjuvants. The objective is to measure toxicity and immunogenicity in these two arms in patients with HLA-A*0201 positive stage IIB, IIC and/or III melanoma. The endpoints are 1) release of gamma-interferon in peripheral blood lymphocytes when exposed to the melanoma-specific peptides and control Ag's; 2) proportion of Ag-specific CD8+ T cells; 3) anti-tumor activity of CD8+ T cells in a dendritic cell (DC)-based cytolysis assay; and 4) toxicity profile. This randomized, controlled, unblinded (pulsed DC group requires leukopheresis) study addresses optimization of immunotherapy in a group of patients shown to be amenable and responsive to this general approach.

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目和 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说，它不一定是研究者的机构。 本研究假设，与用 KLH 和 QS-21 作为佐剂的相同肽制备的疫苗相比，用候选黑色素瘤特异性肽的匙孔血蓝蛋白 (KLH) 脉冲的树突状 Ag 呈递细胞制备的疫苗是细胞毒性 T 淋巴细胞反应的优异“增强剂”。 目的是测量这两个组中 HLA-A*0201 阳性 IIB、IIC 和/或 III 期黑色素瘤患者的毒性和免疫原性。 终点是 1) 当暴露于黑色素瘤特异性肽和对照 Ag 时，外周血淋巴细胞中γ-干扰素的释放； 2) Ag特异性CD8+ T细胞的比例； 3) 基于树突状细胞 (DC) 的细胞溶解测定中 CD8+ T 细胞的抗肿瘤活性； 4) 毒性概况。 这项随机、对照、非盲（脉冲 DC 组需要白细胞去除术）研究针对一组经证明对这种一般方法有顺从且有反应的患者进行免疫治疗的优化。